



# AIDS 2026 pre-conference, "Advancing HIV prevention science and access"

## Programme

<b>08:00 – 09:00</b>	<b>Session 1: Framing the future of HIV prevention: Progress, gaps and the meaning of choice</b> A scene-setting keynote and panel discussion examining what has changed in HIV prevention since AIDS 2024, and interrogating what the concept of "choice" really means for individuals, providers, funders and governments in today's constrained landscape
08:00 – 08:05	<b>Words of welcome</b> Renee Heffron, University of Alabama at Birmingham, US, Co-Chair Thandi Onami, Gates Foundation, US, Co-Chair
08:06 – 08:26	<b>Keynote: What has happened in HIV prevention since AIDS 2024?</b> Beatriz Grinsztejn, Fiocruz, Brazil, and current IAS President
08:27 – 08:54	<b>Panel discussion: Redefining HIV prevention choice</b> Moderator: Renee Heffron, University of Alabama at Birmingham, US, Co-Chair Panellists: <ul style="list-style-type: none"><li>• Artur Kalichman, Ministry of Health, Brazil</li><li>• Elizabeth Irungu, Jhpeigo, Kenya</li><li>• Gastón Devisich, Fundación Huésped, Argentina</li><li>• Ingrid Katz, PEPFAR, US</li><li>• Lloyd Mulenga, Ministry of Health, University of Zambia and University Teaching Hospital, Zambia</li><li>• Paulo dos Santos, Hospital Fernández, Argentina</li></ul>
08:55 – 09:00	<b>Wrap-up: Advocate's perspective</b> Nomonde Ngema, HER Voice Fund, South Africa
09:00 – 09:30	<i>Break</i>



<b>09:30 – 11:00</b>	<b>Session 2: Expanding the biomedical HIV prevention toolbox</b> An overview of the latest advances in antiretroviral-based prevention, including long-acting injectable and implantable technologies, featuring invited talks and oral abstract presentations of recent clinical data	
09:30 – 09:34	Introduction to the session	Renee Heffron, University of Alabama at Birmingham, US, Co-Chair
09:35 – 09:45	Opportunities and challenges with the ARV innovation pile-up	Max Lataillade, Gates Foundation, US
09:46 – 09:56	MK-8527 updates	Rebeca Plank, Merck, US
09:57 – 10:07	Advancing PEP: Innovative study designs for long-acting prevention technologies	Andrew Mujugira, Infectious Diseases Institute, Uganda
10:08 – 10:15	Implants and ultra-long-acting formulations	Rahima Benhabbour, UNC-Chapel Hill, US
10:16 – 10:23	Oral abstract: Global forecast of long-acting PrEP need for key populations (2025-2030)	Micheal Ighodaro, Global Black Gay Men Connect, US
10:24 – 10:31	Oral abstract: Prevention has no age: Post-exposure prophylaxis (PEP) dispensations among older adults in Brazil, 2018-2024	Regina Valim, Federal University of Santa Catarina, Brazil
10:32 – 10:39	Oral abstract: Scaling up HIV prevention in Sri Lanka: Community-based and mobile PrEP delivery	Hemal Fonseka, The Family Planning Association of Sri Lanka, Sri Lanka  Translated by: Mihitha Dasnayaka, The Family Planning Association of Sri Lanka, Sri Lanka
10:40 – 10:50	Community first: Navigating new tools together	Adaobi Lisa Olisa, Root to Rise, Nigeria
10:50 – 11:00	Q&A and interactive discussion	Moderator: Renee Heffron, University of Alabama at Birmingham, US, Co-Chair
11:00 – 11:30	<i>Break</i>	
<b>11:30 – 13:00</b>	<b>Session 3: Basic science shaping the future of HIV prevention: Innovations in HIV vaccine development</b> A deep dive into the science underpinning HIV vaccine candidates, including the latest immunogen research, broadly neutralizing antibody induction and mucosal	



	immune responses, paired with a discussion of why sustained advocacy for vaccine development remains critical	
11:30 – 11:35	<b>Introduction to the session</b>	Thandi Onami, Gates Foundation, US, Co-Chair
11:36 – 11:43	<b>The importance of an HIV vaccine and why advocacy is important</b>	Ntando Yola, DTHF and APHA, South Africa
11:44 – 11:51	<b>Lessons from the IAVI G001–G003 trials and the broader epitope landscape in HIV vaccine development</b>	Eunice Nduati, KEMRI, Kenya (virtual)
11:52 – 11:59	<b>TBC</b>	TBC
12:00 – 12:07	<b>WIN332: Novel V3 Glycan responses in NHP sera</b>	Amelia Escolano, Wistar, US
12:08 – 12:15	<b>V3 Glycan bNAb response: NHP proof of principle data</b>	Jon Steichen, Scripps, US
12:16 – 12:23	<b>Vaccination elicits bNAbs to the HIV Env apex in non-human primates</b>	Javier Guenaga, Scripps, US
12:24 – 12:34	<b>Mucosal immune responses in the female genital tract</b>	Raphael Reyes, Ragon Institute, US
12:35 – 12:45	<b>How the microbiome shapes immune responses in the context of HIV</b>	Douglas Kwon, Ragon Institute, US
12:46 – 13:00	<b>Q&amp;A and interactive discussion</b>	Moderator: Thandi Onami, Gates Foundation, US, Co-Chair
13:00 – 14:00	<p><i>Lunch break and guided poster walks</i></p> <p>Lunch will be provided during the break. Attendees are also invited to join guided poster walks led by IAS HIV Prevention Ambassadors and IAS HIV Vaccine Fellows, offering an opportunity to explore selected posters and engage with presenters.</p>	
<b>14:00 – 15:00</b>	<p><b>Session 4: Maintaining the momentum: From scientific innovation to real-world choice</b></p> <p>A bridging session exploring how today's basic science becomes tomorrow's prevention tools, and what the field must do now to ensure that future discoveries translate into equitable, accessible options for those who need them</p>	
14:00 – 14:05	<b>Introduction to the session</b>	Thandi Onami, Gates Foundation, US, Co-Chair

14:05 – 14:12	<b>Highly networked HIV vaccines</b>	Gaurav Gaiha, Ragon Institute, US
14:13 – 14:20	<b>Controlled release platforms for HIV vaccines</b>	Mariane Melo, Scripps, US
14:21 – 14:25	<b>Q&amp;A and interactive discussion</b>	Moderator: Thandi Onami, Gates Foundation, US
14:26 – 15:00	<b>Panel discussion: Maintaining the momentum for scientific innovation and translating it into real-world choice</b>	Moderator: Max Lataillade, Gates Foundation, US  Panellists: <ul style="list-style-type: none"> <li>• Maureen Luba, Independent, Malawi</li> <li>• Michael Reid, University of California San Francisco (UCSF), US</li> <li>• Nittaya Phanuphak, Institute of HIV Research and Innovation (IHRI), Thailand</li> <li>• Pedro Cahn, Fundación Huésped, Argentina</li> <li>• Thumbi Ndung'u, Africa Health Research Institute (AHRI), South Africa</li> </ul>
15:00 – 15:30	<i>Break</i>	
<b>15:30 – 17:00</b>	<b>Session 5: Delivering prevention: From innovation to real-world choice</b> Country experiences and implementation models for bringing multi-product PrEP programmes to diverse populations, including community-led, pharmacy-based and digital delivery approaches across different health system contexts	
15:30 – 15:35	<b>Introduction to the session</b>	Renee Heffron, University of Alabama at Birmingham, US, Co-Chair
15:36 – 15:46	<b>The South African experience with multi-product PrEP programming (oral, DVR, CAB and LEN)</b>	Hasina Subedar, South Africa NdoH, South Africa
15:47 – 15:57	<b>Delivering PrEP to pregnant and breastfeeding women</b>	Friday Saidi, University of North Carolina (UNC), Malawi
15:58 – 16:08	<b>Pharmacy delivery models</b>	Angela Tembo, Wits Ezintsha, South Africa
16:09 – 16:19	<b>Peer-led strategies for delivering prevention</b>	Ines Dourado, Federal University of Bahia, Brazil
16:20 – 16:30	<b>Automated dispensers and e-health integration, as seen in São Paulo</b>	Adriano Queiroz da Silva, Municipality of São Paulo, Brazil

16:31 – 16:41	<b>Prevention innovation to real-world choice for key and vulnerable populations in Vietnam</b>	Tham Tran, PATH, Vietnam Tin Lu, Glink Vietnam
16:42 – 16:52	<b>How do policy makers determine which programmes to prioritize?</b>	Artur Kalichman, Ministry of Health, Brazil
16:53 – 17:00	<b>Q&amp;A and interactive discussion</b>	Moderator: Renee Heffron, University of Alabama at Birmingham, US, Co-Chair
17:00 – 17:30	<i>Break</i>	
<b>17:30 – 19:00</b>	<b>Session 6: Perspectives and priorities: What will change the course of the pandemic?</b> A closing session of short provocations and open audience discussion, with “hot takes” from leading voices across the field, followed by structured networking to close the day and set priorities for the conference ahead	
17:30 – 17:35	<b>Introduction to the session</b>	Renee Heffron, University of Alabama at Birmingham, US, Co-Chair
17:36 – 18:05	<b>Hot takes: What will actually change the course of the epidemic?</b>	<ul style="list-style-type: none"> <li>• Connie Celum, University of Washington, US</li> <li>• Francois Venter, Wits Ezintsha, South Africa</li> <li>• Tariro Makadzange, Africa Clinical Research Network (ACRN), Zimbabwe</li> </ul>
18:06 – 19:00	<i>Networking reception</i>  Join fellow participants for a networking reception at the end of the day, an opportunity to connect with colleagues, engage with speakers, and continue discussions on key HIV prevention priorities. Refreshments and snacks will be provided.	

## Sponsors

The IAS extends its sincere appreciation to the following organizations for their generous support in making the 2026 HIV prevention pre-conference possible.

